Skip Navigation

Link to  the National Institutes of Health  
The Science of Drug Abuse and Addiction from the National Institute on Drug Abuse Archives of the National Institute on Drug Abuse web site
Go to the Home page

Home > Publications > Research Monographs >    

Medication Development for the Treatment of Cocaine Dependence: Issues in Clinical Efficacy Trials

NIDA Research Monograph, Number 175 [Printed in 1998]

Get Adobe Reader

Complete Monograph - Monograph175.pdf (2.5 MB)

Click on link to go page

Table of Contents

Betty Tai, Charles V. Grudzinskas, Nora Chiang, and Peter Bridge

Goals and Rationale for Pharmacotherapeutic Approach in Treating Cocaine Dependence: Insights From Basic and Clinical Research-----5
Mary Jeanne Kreek

Overview of Potential Treatment Medications for Cocaine Dependence-----36
Elinore F. McCance

Methodologic Recommendations for Cocaine Abuse Clinical Trials: A Clinician-Researcher's Perspective-----73
Edward V. Nunes

Management of Clinical Trials With New Medications for Cocaine Dependence and Abuse-----96
Ari Kiev

Outcome Measurement Considerations: Pharmacological Treatments for Substance Abuse-----118
Karla Moras

Variability in Treatment-Seeking Cocaine Abusers: Implications for Clinical Pharmacotherapy Trials-----137
Kathleen M. Carroll, Charla Nich, and Bruce J. Rounsaville

Baseline Assessment, Study Entry, and Stabilization: Double-Blind Clinical Trials in Drug Dependence-----158
John Grabowski, Gila Arnoni, Ronith Elk, Howard Rhoades, and Joy Schmitz

The Addiction Severity Index in Clinical Efficacy Trials of Medications for Cocaine Dependence-----182
John S. Cacciola, Arthur I. Alterman, Charles P. O'Brien, and A. Thomas McLellan

Cognitive-Neuromotor Assessment of Substance Abuse: Focus on Issues Related to Cocaine Abuse Treatment-----192
E.H. Ellinwood, Jr. and T.H. Lee

Treatment Effectiveness Score as an Outcome Measure in Clinical Trials-----208
Walter Ling, Steven Shoptaw, Donald Wesson, Richard A. Rawson, Margaret Compton, and C. James Klett

Pharmacokinetics of Cocaine: Considerations When Assessing Cocaine Use by Urinalysis-----221
Reese T. Jones

Quantitative Urine Levels of Cocaine and Other Substances of Abuse-----235
Jeffery N. Wilkins

Use of Quantitative Urinalysis in Monitoring Cocaine Use-----253
Kenzie L. Preston, Kenneth Silverman, Charles R. Schuster, and Edward J. Cone

Is Quantitative Urinalysis More Sensitive?-----265
Shou-Hua Li, Nora Chiang, Betty Tai, Charles K. Marschke, and Richard L. Hawks

Comparison of Immunoassays for Semiquantitative Measurement of Benzoylecgonine in Urine-----287
Rodger L. Foltz, Christine Botelho, Scott A. Reuschel, David J. Kuntz, David E. Moody, and Gloria M. Bristow

TAppendix I: Workshop Summary Outcome Measures and Success Criteria-----303
Betty Tai

Appendix II: Workshop Summary Clinical Decision Tree for Cocaine Addiction Pharmacotherapy-----312
Betty Tai, Charles V. Grudzinskas, Peter Bridge, and Nora Chiang

Ordering Information-----318

Archive Home | Accessibility | Privacy | FOIA (NIH) | Current NIDA Home Page
National Institutes of Health logo_Department of Health and Human Services Logo The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. . The U.S. government's official web portal